Salignostics has assembled a team of experts in saliva research and tech and business development, with 15 years of experience in the field. The company has launched three innovative saliva-based diagnostic products: Salistick, SaliCov (COVID-19), and Salicomb (collection device), with Salistick now accessible in over 1,500 retail locations and recognized with a 2023 Time Magazine Best Invention award. The company plans to expand its portfolio to address streptococcus, STDs, and cardiac risk indicators.
Cyborg Score Rationale
Salignostics has achieved commercial traction with a market-proven flagship product (Salistick) reaching 500K+ units and 1,500+ retail locations, plus TIME Magazine recognition. The experienced founding team and IP-backed platform provide competitive moat. However, as a private company with limited disclosed funding and revenue data, and facing entrenched competition in rapid diagnostics, growth trajectory and profitability remain to be demonstrated.
Top Insights
Salistick pregnancy test surpassed 500,000 units sold and is stocked in 1,500+ retail locations across Israel, UK, and Australia, validating market demand for non-invasive saliva diagnostics and establishing distribution channels for pipeline products.
Company holds proprietary lateral flow immunoassay platform that overcomes technical barriers preventing saliva-based testing, creating a defensible technology moat as it expands from pregnancy into COVID-19, Strep A, and sexually transmitted infections.
Strep A (Strep Throat) test in final development stages targets a massive addressable market—Group A Streptococcus affects millions globally—with self-testing capability reducing healthcare burden and enabling direct-to-consumer revenue.